Efficacy of Bozidan (Tanacetum umbelliferum Boiss.) in pain management associated with hyperuricemia: A randomized controlled trial

Abstract

Background and Objective

Hyperuricemia, characterized by elevated uric acid levels in the blood, is often associated with gout and other metabolic disorders. Bozidan (Tanacetum umbelliferum Boiss.), a plant with known anti-inflammatory and antioxidant properties, has been used in Unani medicine. This study aimed to evaluate the efficacy of Bozidan in managing hyperuricemia.

Methods

Twenty-six patients were enrolled, with 13 particpants in each group: intervention and control. Participants were randomly assigned in two groups. The intervention group received Bozidan 4.5 g, divided into three doses, while the control group received Habbe Suranjan (a polyherbal Unani formulation containing Colchicum autumnale L. as a key ingredient) three times daily for 4 weeks. Serum uric acid levels were measured at baseline and at the end of the study. Pain was assessed as a key secondary outcome weekly. Other associated symptoms and adverse effects were also monitored throughout the trial.

Results

Both test and control drugs demonstrated reductions in serum uric acid levels from baseline to the end of the study. However, the reduction in both groups was statistically insignificant (P > 0.05). Improvements were observed in clinical symptoms related to hyperuricemia, such as joint pain, in both groups over the study period. Safety parameters remained within normal limits.

Conclusion

The test drugs demonstrated potential in reducing serum uric acid levels and improving clinical symptoms associated with hyperuricemia. However, further research with larger sample and extended study durations is warranted to conclusively determine its efficacy in lowering serum uric acid levels and its overall clinical benefit.